The O Antigen Is a Critical Antigen for the Development of a Protective Immune Response to Bordetella parapertussis

ABSTRACT Despite excellent vaccine coverage in developed countries, whooping cough is a reemerging disease that can be caused by two closely related pathogens, Bordetella pertussis and B. parapertussis. The two are antigenically distinct, and current vaccines, containing only B. pertussis-derived antigens, confer efficient protection against B. pertussis but not against B. parapertussis. B. pertussis does not express the O antigen, while B. parapertussis retains it as a dominant surface antigen. Since the O antigen is a protective antigen for many pathogenic bacteria, we examined whether this factor is a potential protective antigen for B. parapertussis. In a mouse model of infection, immunization with wild-type B. parapertussis elicited a strong antibody response to the O antigen and conferred efficient protection against a subsequent B. parapertussis challenge. However, immunization with an isogenic mutant lacking the O antigen, B. parapertussis Δwbm, induced antibodies that recognized other antigens but did not efficiently mediate opsonophagocytosis of B. parapertussis. The passive transfer of sera raised against B. parapertussis, but not B. parapertussis Δwbm, reduced B. parapertussis loads in the lower respiratory tracts of mice. The addition of 10 μg of purified B. parapertussis lipopolysaccharide (LPS), which contains the O antigen, but not B. parapertussis Δwbm LPS drastically improved the efficacy of the acellular vaccine Adacel against B. parapertussis. These data suggest that the O antigen is a critical protective antigen of B. parapertussis and its inclusion can substantially improve whooping cough vaccine efficacy against this pathogen.

[1]  M. E. Rodriguez,et al.  O Antigen Allows B. parapertussis to Evade B. pertussis Vaccine–Induced Immunity by Blocking Binding and Functions of Cross-Reactive Antibodies , 2009, PloS one.

[2]  A. Buboltz,et al.  Inefficient Toll-Like Receptor-4 Stimulation Enables Bordetella parapertussis to Avoid Host Immunity , 2009, PloS one.

[3]  E. Vinogradov,et al.  Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates. , 2008, Vaccine.

[4]  D. Wolfe,et al.  O Antigen Protects Bordetella parapertussis from Complement , 2008, Infection and Immunity.

[5]  D Scott Snyder,et al.  Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. , 2007, Microbiology.

[6]  O. Bjørnstad,et al.  The O Antigen Enables Bordetella parapertussis To Avoid Bordetella pertussis-Induced Immunity , 2007, Infection and Immunity.

[7]  Eric T. Harvill,et al.  Comparative Role of Immunoglobulin A in Protective Immunity against the Bordetellae , 2007, Infection and Immunity.

[8]  Paul B. Mann,et al.  Use of a Genetically Defined Double Mutant Strain of Bordetella bronchiseptica Lacking Adenylate Cyclase and Type III Secretion as a Live Vaccine , 2007, Infection and Immunity.

[9]  D. Wolfe,et al.  Different mechanisms of vaccine-induced and infection-induced immunity to Bordetella bronchiseptica. , 2007, Microbes and infection.

[10]  Jianjun Li,et al.  Complete Structures of Bordetella bronchiseptica and Bordetella parapertussis Lipopolysaccharides* , 2006, Journal of Biological Chemistry.

[11]  R. Munford,et al.  Shield as Signal: Lipopolysaccharides and the Evolution of Immunity to Gram-Negative Bacteria , 2006, PLoS pathogens.

[12]  Eric T. Harvill,et al.  The Bordetella bronchiseptica Type III Secretion System Inhibits Gamma Interferon Production That Is Required for Efficient Antibody-Mediated Bacterial Clearance , 2006, Infection and Immunity.

[13]  P. Sansonetti,et al.  Characterization of Functional Oligosaccharide Mimics of the Shigella flexneri Serotype 2a O-Antigen: Implications for the Development of a Chemically Defined Glycoconjugate Vaccine1 , 2006, The Journal of Immunology.

[14]  Paul B. Mann,et al.  Comparative Toll-Like Receptor 4-Mediated Innate Host Defense to Bordetella Infection , 2005, Infection and Immunity.

[15]  O. Bjørnstad,et al.  Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. , 2005, The Journal of clinical investigation.

[16]  D. Wolfe,et al.  Clearance of Bordetella parapertussis from the Lower Respiratory Tract Requires Humoral and Cellular Immunity , 2005, Infection and Immunity.

[17]  Seema Mattoo,et al.  Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies , 2005, Clinical Microbiology Reviews.

[18]  Mineo Watanabe,et al.  Whooping cough due to Bordetella parapertussis: an unresolved problem , 2004, Expert review of anti-infective therapy.

[19]  W. Hryniewicz,et al.  Epidemiology and characterization of Bordetella parapertussis strains isolated between 1995 and 2002 in and around Warsaw, Poland , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[20]  F. Mooi,et al.  Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. , 2004, Vaccine.

[21]  D. Relman,et al.  Bordetella Species Are Distinguished by Patterns of Substantial Gene Loss and Host Adaptation , 2004, Journal of bacteriology.

[22]  J. Cherry,et al.  Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  M. Kennett,et al.  Antibody‐mediated bacterial clearance from the lower respiratory tract of mice requires complement component C3 , 2004, European journal of immunology.

[24]  M. Maixnerová.  The 2001 serological survey in the Czech Republic--pertussis. , 2003, Central European journal of public health.

[25]  B. Barrell,et al.  Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica , 2003, Nature Genetics.

[26]  J. Liese,et al.  Clinical and epidemiological picture of B pertussis and B parapertussis infections after introduction of acellular pertussis vaccines , 2003, Archives of disease in childhood.

[27]  Paul B. Mann,et al.  Role of Antibodies in Immunity to Bordetella Infections , 2003, Infection and Immunity.

[28]  M. E. Rodriguez,et al.  Fc Receptor-Mediated Immunity Against Bordetella pertussis1 , 2001, The Journal of Immunology.

[29]  K. Mills.  Immunity to Bordetella pertussis. , 2001, Microbes and infection.

[30]  J. V. D. van de Winkel,et al.  Flow cytometry-based phagocytosis assay for sensitive detection of opsonic activity of pneumococcal capsular polysaccharide antibodies in human sera. , 2001, Journal of immunological methods.

[31]  F. Mooi,et al.  Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. , 2000, Emerging infectious diseases.

[32]  B. Barrell,et al.  Genetic Basis for Lipopolysaccharide O-Antigen Biosynthesis in Bordetellae , 1999, Infection and Immunity.

[33]  M. Peppler,et al.  Fluorescent Labels Influence Phagocytosis ofBordetella pertussis by Human Neutrophils , 1999, Infection and Immunity.

[34]  H. Schmitt,et al.  Evaluation of a Single-Sample Serological Technique for Diagnosing Pertussis in Unvaccinated Children , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[35]  H. Colten,et al.  Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. , 1999, Immunopharmacology.

[36]  J. Cherry,et al.  Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  J. Taranger,et al.  Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses. , 1999, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[38]  J. Mertsola,et al.  Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. , 1998, JAMA.

[39]  J. Cherry,et al.  The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in respiratory mouse model. , 1998, Vaccine.

[40]  D. Maskell,et al.  Molecular and functional analysis of the lipopolysaccharide biosynthesis locus wlb from Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica , 1998, Molecular microbiology.

[41]  W. M. R. Akker.  Lipopolysaccharide expression within the genus Bordetella: influence of temperature and phase variation , 1998 .

[42]  M. L. Ciofi Degli Atti,et al.  Bordetella parapertussis Infection in Children: Epidemiology, Clinical Symptoms, and Molecular Characteristics of Isolates , 1998, Journal of Clinical Microbiology.

[43]  F. Mooi,et al.  The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model. , 1998, Vaccine.

[44]  F. Mooi,et al.  Molecular evolution and host adaptation of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three insertion sequences , 1997, Journal of Bacteriology.

[45]  H. Schmitt,et al.  Epidemiologic aspects and diagnostic criteria for a protective efficacy field trial of a pertussis vaccine. , 1996, The Journal of infectious diseases.

[46]  D. Maskell,et al.  The identification, cloning and mutagenesis of a genetic locus required for lipopolysaccharide biosynthesis in Bordetella pertussis , 1996, Molecular microbiology.

[47]  J. Cherry,et al.  Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. , 1994, The Pediatric infectious disease journal.

[48]  K. Mills,et al.  Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model , 1993, Infection and immunity.

[49]  N. Guiso,et al.  Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species , 1993, Infection and immunity.

[50]  T. Makarenko,et al.  Specific and non-specific mouse protection induced by different chemotypes of the Pseudomonas aeruginosa lipopolysaccharides. , 1992, FEMS microbiology immunology.

[51]  H. Iro,et al.  Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. , 1991, Blood.

[52]  S. Stibitz,et al.  Subcellular localization and immunological detection of proteins encoded by the vir locus of Bordetella pertussis , 1991, Journal of bacteriology.

[53]  H. Finger,et al.  Use of supplemented Stainer-Scholte broth for the isolation of Bordetella pertussis from clinical material , 1988, Journal of clinical microbiology.

[54]  R. Rappuoli,et al.  Promoter of the pertussis toxin operon and production of pertussis toxin , 1987, Journal of bacteriology.

[55]  F. Mooi,et al.  Characterization of fimbrial subunits from Bordetella species. , 1987, Microbial pathogenesis.

[56]  R. Rappuoli,et al.  Expression and immunological properties of the five subunits of pertussis toxin , 1987, Infection and immunity.

[57]  D W Stainer,et al.  A simple chemically defined medium for the production of phase I Bordetella pertussis. , 1970, Journal of general microbiology.

[58]  T. Buchanan,et al.  Pertussis in the United States. , 1970, The Journal of infectious diseases.

[59]  M. Maixnerová.  The 2001 serological survey in the Czech Republic--parapertussis. , 2003, Central European journal of public health.

[60]  Pertussis--United States, 1997-2000. , 2002, MMWR. Morbidity and mortality weekly report.

[61]  D. Maskell,et al.  Multiple Roles for Bordetella Lipopolysaccharide Molecules during Respiratory Tract Infection , 2000 .

[62]  W. V. D. van den Akker.  Lipopolysaccharide expression within the genus Bordetella: influence of temperature and phase variation. , 1998, Microbiology.

[63]  M. Šimkovicová,et al.  Studies on the circulation of bordetella pertussis and bordetella parapertussis in populations of children. , 1972, Journal of hygiene, epidemiology, microbiology, and immunology.